Mizuho healthcare sector expert Jared Holz explained: "Now without a GLP in its (near-term) pipeline, it is now feasible that PFE could look to bring in an asset (external business development) should it choose to stay in the weight-loss game to some extent." Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics
Clin J Am Soc Nephrol (2017) 12(8):136673
This drug, whose generic name is semaglutide, falls into the category of glucagon-like peptide-1 (GLP-1) receptor agonists
Weekly: A Realistic Metric Focusing on weekly weight loss can be misleading because day-to-day fluctuations in hydration, sodium, hormones, and digestion create noise in the data
The associated cost-of-living issue spells danger of bringing about a two tier system, in which treatment effectiveness is based on who has the ability to pay for and has access to comprehensive and continuous support, while others just suffer from widening health inequality.
he asked me what the issue was or if I was having a problem
